Patent foramen ovale (PFO) is the most common congenital heart abnormality of fetal origin
and is present in approximately∼ 25% of the worldwide adult population. PFO is the …

Percutaneous closure has evolved to become the first-line treatment strategy for most cases
of secundum atrial septal defect (ASD) in both adults and children. Its safety and efficacy …

Background—Transcatheter closure of secundum atrial septal defects (ASD) using the
Amplatzer septal occluder is generally safe and effective, but erosion into the pericardial …

OBJECTIVE: Amplatzer (AGA Medical Corporation, Plymouth, Minn) septal and vascular
occluder devices have significantly altered the care of patients with congenital heart …

Objective To systematically review all cases in the literature of erosion associated with Atrial
Septal Defect (ASD) occluder devices. Background Delayed erosion of the aortic or atrial …

Aims Percutaneous patent foramen ovale (PFO) closure for secondary stroke prevention is
discussed controversially. Long-term data comparing different closure devices are limited …

Degradable heart occluders are a promising replacement for currently clinically used non-
degradable ones without concerns about the complications caused by the persistent residue …

We report a case of late infective endocarditis in an 8‐year‐old boy 3 years after
transcatheter closure of an atrial septal defect with the Amplatzer Atrial Septal Occluder …

3 Executive summary Requirements for cardiac catheterization procedures in pediatric
patients and patients with CHD differ greatly from adult coronary or structural interventions …

The purpose of this review is to describe the current state of the art in terms of available
devices and indications for the transcatheter device closure of atrial septal defects (ASD) …